1. subjects with spo2 \>94% on room air using pulse oximetry and without bilateral infiltrates on chest imaging 2. subjects requiring mechanical ventilation or extracorporeal membrane oxygenation 3. patients with stage 5 ckd receiving renal replacement therapy with either hemodialysis or peritoneal dialysis, renal transplant or with egfr \<15 ml/min/1.73 m2. 4. patients with prior transplantations of organs or bone marrow. 5. patients with unstable cardiac condition including heart attack, stroke, uncontrolled atrial fibrillation or a major cardiac procedure within 3 months as assessed by the investigator. 6. new york heart association class iv congestive heart failure. 7. evidence of cirrhosis from liver imaging or biopsy, a history of hepatic encephalopathy, esophageal or gastric varices, active hepatitis, or prior porta-caval shunt procedure. 8. alt or ast \>5 x uln on admission laboratory assessment. 9. total bilirubin \>2 x uln on admission laboratory assessment. 10. have received any live attenuated vaccine within 90 days at dosing. 11. known human immunodeficiency virus positive patients. 12. chronic use of oxygen therapy at home 13. have participated in a clinical study and received any investigational medication within the last 30 days preceding visit 1 (screening). 14. subjects whose safety may be compromised by study participation 15. are not, in the opinion of the investigator, able or willing to comply with the protocol.

1. subjects with spo2 \>94% on room air using pulse oximetry and without bilateral infiltrates on chest imaging 2. subjects requiring mechanical ventilation or extracorporeal membrane oxygenation 3. patients with stage 5 ckd receiving renal replacement therapy with either hemodialysis or peritoneal dialysis, renal transplant or with egfr \<15 ml/min/1.73 m2. 4. patients with prior transplantations of organs or bone marrow. 5. patients with unstable cardiac condition including heart attack, stroke, uncontrolled atrial fibrillation or a major cardiac procedure within 3 months as assessed by the investigator. 6. new york heart association class iv congestive heart failure. 7. evidence of cirrhosis from liver imaging or biopsy, a history of hepatic encephalopathy, esophageal or gastric varices, active hepatitis, or prior porta-caval shunt procedure. 8. alt or ast \>5 x uln on admission laboratory assessment. 9. total bilirubin \>2 x uln on admission laboratory assessment. 10. have received any live attenuated vaccine within 90 days at dosing. 11. known human immunodeficiency virus positive patients. 12. chronic use of oxygen therapy at home 13. have participated in a clinical study and received any investigational medication within the last 30 days preceding visit 1 (screening). 14. subjects whose safety may be compromised by study participation 15. are not, in the opinion of the investigator, able or willing to comply with the protocol.

subjects with spo2 >94% on room air using pulse oximetry and without bilateral infiltrates on chest imaging subjects requiring mechanical ventilation or extracorporeal membrane oxygenation patients with stage 5 ckd receiving renal replacement therapy with either hemodialysis or peritoneal dialysis, renal transplant or with egfr <15 ml/min/1.73 m2. patients with prior transplantations of organs or bone marrow. patients with unstable cardiac condition including heart attack, stroke, uncontrolled atrial fibrillation or a major cardiac procedure within 3 months as assessed by the investigator. new york heart association class iv congestive heart failure. evidence of cirrhosis from liver imaging or biopsy, a history of hepatic encephalopathy, esophageal or gastric varices, active hepatitis, or prior porta-caval shunt procedure. alt or ast >5 x uln on admission laboratory assessment. total bilirubin >2 x uln on admission laboratory assessment. have received any live attenuated vaccine within 90 days at dosing. known human immunodeficiency virus positive patients. chronic use of oxygen therapy at home have participated in a clinical study and received any investigational medication within the last 30 days preceding visit 1 (screening). subjects whose safety may be compromised by study participation are not, in the opinion of the investigator, able or willing to comply with the protocol.

subjects with spo2 >94% on room air using pulse oximetry and without bilateral infiltrates on chest imaging subjects requiring mechanical ventilation or extracorporeal membrane oxygenation patients with stage 5 ckd receiving renal replacement therapy with either hemodialysis or peritoneal dialysis, renal transplant or with egfr <15 ml/min/1.73 m2. patients with prior transplantations of organs or bone marrow. patients with unstable cardiac condition including heart attack, stroke, uncontrolled atrial fibrillation or a major cardiac procedure within 3 months as assessed by the investigator. new york heart association class iv congestive heart failure. evidence of cirrhosis from liver imaging or biopsy, a history of hepatic encephalopathy, esophageal or gastric varices, active hepatitis, or prior porta-caval shunt procedure. alt or ast >5 x uln on admission laboratory assessment. total bilirubin >2 x uln on admission laboratory assessment. have received any live attenuated vaccine within 90 days at dosing. known human immunodeficiency virus positive patients. chronic use of oxygen therapy at home have participated in a clinical study and received any investigational medication within the last 30 days preceding visit 1 (screening). subjects whose safety may be compromised by study participation are not, in the opinion of the investigator, able or willing to comply with the protocol.

1. subjects with spo2 >94% on room air using pulse oximetry and without bilateral infiltrates on chest imaging 2. subjects requiring mechanical ventilation or extracorporeal membrane oxygenation 3. patients with stage 5 ckd receiving renal replacement therapy with either hemodialysis or peritoneal dialysis, renal transplant or with egfr <15 ml/min/1.73 m2. 4. patients with prior transplantations of organs or bone marrow. 5. patients with unstable cardiac condition including heart attack, stroke, uncontrolled atrial fibrillation or a major cardiac procedure within 3 months as assessed by the investigator. 6. new york heart association class iv congestive heart failure. 7. evidence of cirrhosis from liver imaging or biopsy, a history of hepatic encephalopathy, esophageal or gastric varices, active hepatitis, or prior porta-caval shunt procedure. 8. alt or ast >5 x uln on admission laboratory assessment. 9. total bilirubin >2 x uln on admission laboratory assessment. 10. have received any live attenuated vaccine within 90 days at dosing. 11. known human immunodeficiency virus positive patients. 12. chronic use of oxygen therapy at home 13. have participated in a clinical study and received any investigational medication within the last 30 days preceding visit 1 (screening). 14. subjects whose safety may be compromised by study participation 15. are not, in the opinion of the investigator, able or willing to comply with the protocol.

1. subjects with spo2 >94% on room air using pulse oximetry and without bilateral infiltrates on chest imaging 2. subjects requiring mechanical ventilation or extracorporeal membrane oxygenation 3. patients with stage 5 ckd receiving renal replacement therapy with either hemodialysis or peritoneal dialysis, renal transplant or with egfr <15 ml/min/1.73 m2. 4. patients with prior transplantations of organs or bone marrow. 5. patients with unstable cardiac condition including heart attack, stroke, uncontrolled atrial fibrillation or a major cardiac procedure within 3 months as assessed by the investigator. 6. new york heart association class iv congestive heart failure. 7. evidence of cirrhosis from liver imaging or biopsy, a history of hepatic encephalopathy, esophageal or gastric varices, active hepatitis, or prior porta-caval shunt procedure. 8. alt or ast >5 x uln on admission laboratory assessment. 9. total bilirubin >2 x uln on admission laboratory assessment. 10. have received any live attenuated vaccine within 90 days at dosing. 11. known human immunodeficiency virus positive patients. 12. chronic use of oxygen therapy at home 13. have participated in a clinical study and received any investigational medication within the last 30 days preceding visit 1 (screening). 14. subjects whose safety may be compromised by study participation 15. are not, in the opinion of the investigator, able or willing to comply with the protocol.